NovaBay Pharmaceuticals, Inc.  

(Public, NYSEMKT:NBY)   Watch this stock  
Find more results for NBY
+0.20 (5.33%)
Jan 13 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 3.65 - 4.07
52 week 1.77 - 5.29
Open 3.65
Vol / Avg. 29,087.00/24,242.00
Mkt cap 62.97M
P/E     -
Div/yield     -
EPS -3.21
Shares 15.13M
Beta -0.22
Inst. own 1%
Mar 1, 2017
Q4 2016 NovaBay Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 10, 2016
Q3 2016 NovaBay Pharmaceuticals Inc Earnings Call
Nov 10, 2016
Q3 2016 NovaBay Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -108.67% -433.07%
Operating margin -58.55% -479.66%
EBITD margin - -475.92%
Return on average assets -135.33% -300.82%
Return on average equity -705.01% -
Employees 23 -
CDP Score - -


2000 Powell St Ste 1150
EMERYVILLE, CA 94608-1804
United States - Map
+1-510-8998800 (Phone)
+1-510-2250371 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Officers and directors

Mark M. Sieczkarek Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Thomas J Paulson Chief Financial Officer, Treasurer, Secretary, IR Contact Officer
Age: 69
Bio & Compensation  - Reuters
Russell A. Hoon Senior Vice President - Advanced wood care
Age: 62
Bio & Compensation  - Reuters
David W. Stroman Ph.D. Senior Vice President - Ophthalmic Product Development
Age: 70
Bio & Compensation  - Reuters
Xinzhou Li Director
Age: 51
Bio & Compensation  - Reuters
Yonghao Ma Ph.D. Director
Bio & Compensation  - Reuters
Todd E. Zavodnick Director
Bio & Compensation  - Reuters
Paul E. Freiman Independent Director
Age: 81
Bio & Compensation  - Reuters
Gail J. Maderis Independent Director
Age: 57
Bio & Compensation  - Reuters